Financial Performance - Revenue for the three months ended September 30, 2024, was $42.548 million, a decrease of 9.6% compared to $46.793 million for the same period in 2023[8] - Operating expenses for the three months ended September 30, 2024, totaled $46.264 million, an increase of 0.9% from $45.838 million in the prior year[8] - Net loss for the three months ended September 30, 2024, was $6.040 million, compared to a net loss of $1.667 million for the same period in 2023[8] - Basic loss per share for the three months ended September 30, 2024, was $(0.10), compared to $(0.03) for the same period in 2023[8] - Comprehensive loss for the three months ended September 30, 2024, was $5.834 million, compared to a comprehensive loss of $1.773 million for the same period in 2023[11] - For the nine months ended September 30, 2024, the net loss was $3,217,000, while the previous year showed a net income of $95,000[16] - Cash flows from operating activities for the nine months ended September 30, 2024, provided $8,637,000, down from $19,090,000 in the prior year[16] Assets and Liabilities - Total current assets decreased to $12.892 million as of September 30, 2024, from $15.961 million as of December 31, 2023[7] - Total liabilities increased to $125.708 million as of September 30, 2024, compared to $120.027 million as of December 31, 2023[7] - Cash and cash equivalents decreased to $5.972 million as of September 30, 2024, from $10.262 million as of December 31, 2023[7] - Total assets increased to $208.245 million as of September 30, 2024, compared to $204.019 million as of December 31, 2023[7] - Total debt, net as of September 30, 2024, was $70.1 million, a decrease from $71.6 million as of December 31, 2023[53] Equity and Compensation - The company recorded a cumulative reversal of stock compensation expense of $10.4 million during the first quarter of fiscal year 2024[8] - The total equity-based compensation for the nine months ended September 30, 2024, was $1,522,000, significantly lower than $13,483,000 in the prior year[16] - The Company recognized equity-based compensation expenses of $3.4 million for the three months ended September 30, 2024, down from $4.5 million in 2023, and $1.5 million for the nine months ended September 30, 2024, compared to $13.5 million in 2023[63] - The Company granted 515,804 restricted stock units (RSUs) during the nine months ended September 30, 2024, compared to 767,261 RSUs in the same period of 2023, representing a decrease of 32.8%[60] Expenses - Advertising expenses for the three months ended September 30, 2024, were approximately $6.9 million, compared to $6.5 million for the same period in 2023, reflecting a 6.2% increase[39] - The Company incurred rent expenses of $1.8 million and $5.0 million for the three and nine months ended September 30, 2024, respectively, compared to $1.5 million and $4.4 million for the same periods in 2023, indicating a year-over-year increase of 20% and 13.6%[55] - The company reported depreciation and amortization of $8,693,000 for the nine months ended September 30, 2024, compared to $7,479,000 in the previous year[16] - Depreciation expense for the three months ended September 30, 2024, was approximately $1.8 million, compared to $1.4 million for the same period in 2023, representing a 28.6% increase[49] Tax and Compliance - The effective tax rate for the three months ended September 30, 2024, was approximately (13.8)%, a significant improvement from (89.2)% in the same period of 2023[43] - The income tax expense for the three months ended September 30, 2024, was $0.7 million, down from $0.8 million in 2023, while the nine-month tax expense decreased from $2.5 million in 2023 to $0.9 million in 2024[68] - The Company is in compliance with all covenants under its Credit Agreement and has no letters of credit outstanding as of September 30, 2024[54] Future Outlook - The company anticipates potential impacts from rising interest rates and increased competition in the weight loss market[4] - Total future minimum rental payments under non-cancellable operating lease agreements amount to $45.981 million, with $1.777 million due in 2024 and $7.445 million in 2025[59] - Amortization of intangible assets will be $4.8 million per year for each of the next five fiscal years[46]

Financial Data and Key Metrics - Revenue for Q3 2024 was $42.5 million, down 9.1% YoY, with case volume declining 4.3% YoY [8] - Same-store cases declined 8.1% YoY, an improvement from the 14% decline in Q2 2024 [8] - Adjusted EBITDA was $4.7 million, or 11% of revenue, compared to $9.1 million, or 19.4% of revenue, in Q3 2023 [8] - Average revenue per case was $12,984, on the high side of the $12,000 to $13,000 range, but down from $13,658 in Q3 2023 [15] - Customer acquisition cost (CAC) was $2,900 per case, up from $2,750 in the prior year [17] Business Line Performance - The company opened four new centers in Q3 2024: Kansas City, Columbus, Deerfield, and Birmingham, with a fifth center in White Plains expected to open soon [13] - The 2023 de novo centers are performing ahead of the $4.5 million first-year revenue target, with a payback period of less than one year [12] - The company operated 31 facilities as of September 30, 2024, up from 27 in Q3 2023 [13] Market Performance - The company is seeing measured improvement in converting leads to consultations, attributed to a more targeted advertising approach [9] - The percentage of patients using financing for procedures remained consistent at 53% [16] - The company is exploring opportunities to extend payment options for qualified customers, potentially increasing revenue per case [31] Strategic Initiatives and Industry Competition - The company is focusing on three back-to-basics priorities: improving lead-to-case conversion, ensuring successful de novo center openings, and better cost management [7] - The company is leveraging Salesforce to reconnect with customer leads and improve conversion rates [11] - The company is exploring opportunities in skin tightening procedures, particularly in response to the growing use of GLP-1 drugs [26][27] Management Commentary on Operating Environment and Future Outlook - The company is navigating a challenging consumer spending environment, with lower case and lead volumes impacting revenue [15] - The company expects to achieve $2 million in annualized cost savings and plans to reinvest savings into higher-return marketing activities [14] - The company increased its 2024 revenue guidance midpoint to $183 million to $189 million and maintained its adjusted EBITDA guidance of $23 million to $28 million [19] Other Important Information - The company promoted Philip Bodie to Chief Accounting Officer, citing his significant experience in the healthcare industry [20] - The search for a permanent CEO is ongoing, with several interviews conducted and an announcement expected soon [21] Q&A Session Summary Question: New Center Ramp-Up and Contribution Expectations - The four new centers opened in Q3 contributed 530 cases, with Deerfield and Birmingham contributing minimally due to late-quarter openings [23] - The company expects a significant improvement in Q4, with centers potentially doubling their Q3 case volume [24] Question: Impact of GLP-1 Drugs on Demand - The company has not seen significant changes in demand due to GLP-1 drugs but is exploring opportunities in skin tightening procedures [26][27] Question: New Payment Options for Consumers - The company is extending payment options for qualified customers, potentially increasing revenue per case and volume [31] Question: Cost of Service Increase and Future Expectations - The increase in cost of service was driven by new center openings and pre-opening costs, with improvement expected in Q4 as centers ramp up [36][37] Question: SG&A Spend and Future Outlook - The company reduced marketing spend by $4.1 million sequentially and expects a slight uptick in Q4, focusing on optimizing marketing spend [40][41] - Corporate overhead reductions of $0.5 million are expected to continue into Q4 and 2025 [42]

AirSculpt Technologies, Inc. (AIRS) reported $42.55 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 9.1%. EPS of -$0.02 for the same period compares to $0.05 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $42.49 million, representing a surprise of +0.14%. The company delivered an EPS surprise of -150.00%, with the consensus EPS estimate being $0.04. While investors closely watch year-over-year changes in headline numbers -- reve ...

AirSculpt Technologies, Inc. (AIRS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -150%. A quarter ago, it was expected that this company would post earnings of $0.13 per share when it actually produced earnings of $0.09, delivering a surprise of -30.77%. Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 AirSculpt Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) | --- | --- | --- | |------------------------------------|--------------------------|----------------------------------| | | | | | (State or Other Jurisdiction | (Commission | (IRS Employer | | ...

MIAMI BEACH, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the third quarter and nine months ended September 30, 2024. “Our revenue and Adjusted EBITDA for the quarter were in line with our expectations with the period including progress on our strategy despite continued challenges in the consumer environment,” said Dennis Dean, Interim Chief Executive Of ...

AirSculpt Technologies, Inc. (AIRS) shares ended the last trading session 14.2% higher at $6.69. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.4% gain over the past four weeks.The stock benefits from the company's innovative, minimally invasive body contouring technology that appeals to a growing cosmetic market. Strong brand recognition and a favorable industry trend toward non-surgical treatments make AIRS s ...

Expects 2024 Revenue in the Range of $183 Million to $189 Million Announces Third Quarter Fiscal 2024 Earnings Date and Conference Call MIAMI BEACH, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced selected unaudited preliminary financial results for its third quarter ended September 30, 2024. For the third quarter, revenue is expected to be approximately $42.5 million ...

AirSculpt Technologies, Inc. (AIRS) shares rallied 5.6% in the last trading session to close at $5.68. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 33.5% gain over the past four weeks.The stock is benefiting from the improved performance of the company’s new centers, which have surpassed the ROI expectations despite the challenging customer environment.This company is expected to post quarterly earnings of ...

MIAMI BEACH, Fla., Oct. 1, 2024 /PRNewswire/ -- AirSculpt® Technologies, Inc., ("AirSculpt") (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced the opening of its Birmingham office at 555 S. Old Woodward Avenue Suite 500, Birmingham, MI 48009, increasing its center count to 31 locations. The center has been artfully designed and is complete with two operating rooms allowing for concurrent procedures. Also, the company's popular AirSculpt®+ skin tightening p ...